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S276 Poster Session IBreakthrough fungal infections were observed in 4 (6%) and 11
(15%) patients in the L-ampho B and the caspofungin groups, re-
spectively (p 5 0.2). Of all, 13 were due to Aspergillus spp while 1
C. neoformans CNS infection and 1 B. capitatus fungemia were ob-
served in patients receiving caspofungin. Nine additional patients
had a baseline fungal infection (4 in the L-ampho B group and 5 in
the caspofungin group) and none of them had successful treatment.
Resolution of fever during neutropenia was seen in 40 (66%) and 41
(56%) of patients in the L-ampho B and the caspofungin groups,
respectively (p5 0.17). There was a trend towards higher premature
discontinuation of therapy due to lack of efficacy or toxicity in the
caspofungin group (27% vs 13%, p 5 0.057). However, more pa-
tients survived at least 7 days after completion of therapy in the cas-
pofungin group (92% vs 75%, p 5 0.007). The overall success rate
defined as the fulfilment of all 5 composite end points was achieved
in 28 (46%) and 24 (33%) patients in the L-ampho B and the caspo-
fungin groups, respectively (p 5 0.16).
L-ampho B and caspofungin were both effective when given as
empirical antifungal therapy for the treatment of PFN in patients un-
dergoing allogeneic SCT. Differences between L-ampho B and cas-
pofungin in overall success assessed by the 5-component end point
were not statistically significant.336
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Background:The number of Hematopoietic StemCell Transplants
(HSCT) has increased over the past 25 years with higher rates of
success and a large number of long-term survivors. Patients who un-
dergo either an autologous or allogeneic HSCT experience pro-
found immunosuppression from the conditioning regimen causing
them to lose the immunity gained from previous vaccinations. Ac-
knowledging the need for consistency among practices, the Centers
for Disease Control and Prevention, Infectious Disease Society of
America, and the American Society of Blood and Marrow Trans-
plantation published guidelines regarding re-immunization post
HSCT in 2000.
Purpose: The purpose of this study was to assess patient adherence
to re-immunization guidelines after HSCT. Completeness, timeli-
ness, factors influencing adherence and parental identification of
barriers to re-immunization were also examined.
Methods: Patients who received anHSCTbetween 01/01/2001 and
12/31/2007 and were alive at time of recruitment were eligible for
enrollment. Parents of eligible patients were contacted to participate
in a phone survey assessing perceptions of and barriers to re-immu-
nization. Vaccination data was abstracted using theGeorgia Registry
of Immunization Transactions and Services (GRITS), a state-wide
mandatory reporting database for Georgia.
Results: Of the 271 patients transplanted during the designated
time period, 98 met eligibility criteria and 58 completed the phone
survey. Of the phone survey participants, 90% (N 5 58) reported
being told their child would need to be re-immunized post HSCT
and 89% (N 5 57) reported their child being up to date on immu-
nizations to the best of their knowledge. Data in GRITS, however,
showed that only 9% (N 5 98) had completed all doses of 6 of the
recommended vaccines (Hep B, HiB, MMR, Polio, PPV, DTaP/
Td). On average patients who had received at least one post-
HSCT vaccination completed 60% of the recommended doses
(N 5 87). Patients who received allogeneic transplants averaged
63% (N 5 56) complete while patients who received autologous
averaged 54% (N 5 31) complete. The guidelines recommend pa-
tients begin re-immunization 365 days post HSCT. The average
time to first immunization post HSCT was 639 days (median
512 days, range 195 – 2728 days).
Conclusion: Parents perceived their children to be more up to date
with their re-immunizations than was found in GRITS data. Further
education is needed for both parents and healthcare providers caring
for these patients.337
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Backgrounds: Although drug interaction between calcineurin in-
hibitors and voriconazole has been recognized, the interaction has
not been fully evaluated in hematopoietic stem cell transplantation
(HSCT) recipients. We have previously shown a notably wide vari-
ability in the effect of voriconazole administration on the concentra-
tion of calcineurin inhibitors in HSCT recipients, in whom
voriconazole and calcineurin inhibitors were administered orally or
intravenously (Bone Marrow Transplant 2009;44:371). In the pres-
ent study, the drug interaction between voriconazole and tacrolimus
was evaluated in HSCT recipients, when both were orally adminis-
tered. In addition, bioavailability of voriconazole was evaluated
and its association with the drug interaction was quantitatively
assessed.
Patients & Methods: Twenty-two recipients of allogeneic HSCT
who had already been on a steady dose of orally administered tacro-
limus, and were started on voriconazole (orally 200 mg per body ev-
ery 12 h) for the treatment or prophylaxis of fungal infection were
evaluated. Conditioning were myeloablative in 12 patients, and re-
duced-intensity in 8 patients. The concentration/dose (C/D; (ng/
ml)/(mg/kg)) ratio of calcineurin inhibitors was calculated before
and 7–10 days after initiating voriconazole administration. The C/
D ratios before and after voriconazole administration were com-
pared, and increased rate (%) was calculated. The plasma level of
voriconazole was measured by high-performance liquid chromatog-
raphy.
Results:Themedian C/D ratio of tacrolimus significantly increased
to 531.1 (ng/ml)/(mg/kg) (range, 127.8-759.2) after initiating vori-
conazole administration as compared with that before (169.6 (range,
128.6-541.3): P\0.001). Median increased rate of C/D ratios were
196.8% with a range of -32.0% to 685.7%. The plasma level of vor-
iconazole on the day of evaluating C/D ratio was 2.3961.67 mg/ml,
which was lower than 1.0 mg/ml in 4 patients and higher than 4.0
mg/ml in 3 patients. The increased rate of C/D ratio of tacrolimus
did not correlate with the plasma level of voriconazole (r 5 -0.05,
P 5 0.838).
Conclusion: Orally administered voriconazole demonstrates
a significant interaction with orally administered tacrolimus with
a wide interindividual variability in the magnitude. A wide interindi-
vidual variability could not be explained by the difference in the bio-
availability of voriconazole, and other mechanisms such as p-gp
should be investigated.338
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Parainfluenza virus (PIV) infections are common after allogeneic
SCT and can cause severe morbidity, yet there is no effective treat-
ment. DAS181 is an investigational antiviral medication which is ac-
tive in vitro and in vivo against PIV. It is a recombinant sialidase
protein which removes sialic acid residues. Binding to these residues
is the initial step in PIV infection. We report the first treatment of
PIV3 infection with DAS181 in a SCT patient. A 63 year-old female
with AMLunderwent a second SCT after primary graft failure. Con-
ditioning included fludarabine and alemtuzumab, with tacrolimus as
GVHD prophylaxis. After engraftment, her course was complicated
by grade III skin GVHD which was treated with steroids and myco-
phenolate mofetil. Three months after her second SCT, she devel-
oped nasal congestion and cough and was found to have PIV3
infection. She was treated with bronchodilators and IVIG. There
was no evidence of superinfection. She was admitted 6 weeks later
for pancytopenia and worsening respiratory status thought to be
from progressive PIV3 infection. Given her worsening status, we ob-
tained an emergency IND from the FDA to administer DAS181.
Poster Session I S277The patient was treated with a dose of 10 mg daily inhaled for 3 con-
secutive days. She tolerated the therapy well. Within one day of ini-
tiating treatment, the patient subjectively felt better. She did not
require supplemental oxygen by day 3 of therapy and was discharged.
Initial pulmonary function tests (PFTs) showed FEV1 of 0.76L and
DLCO was 36% of predicted. Subsequent PFTs showed FEV1 of
0.91L and DLCO was 53% of predicted. Serial samples from nasal
and oral sites were taken and showed reduction of PIV virus loads
as measured by PCR.
Table 1. Parainfluenza viral load as measured by PCR from
oral and nasal sites
Day Site PIV3 copies / ml1 Oral 1.47 E4
3 Oral 2.90 E3
1 Nasal 1.72 E7
3 Nasal 7.30 E4In vitro testing of the infecting PIV strain showed an inhibitory
dose between 10-100 nM. One week later, the patient’s respiratory
symptoms worsened. She was found to have evidence of persistent
PIV3 infection as well as relapse of AML. Treatment was initiated
with a second course of DAS181, but her AML progressed rapidly
and she died from complications of AML. The cause of death was
unrelated to PIV infection. Treatment with inhaled DAS181 clearly
brought about a clinical improvement as evidenced by improved
symptoms, PFTs, exam, and decrease in PIV virus load. Longer
treatment may be required in SCT recipients. DAS181 administra-
tion for treatment of PIV infections should be systematically tested
in patient groups at risk for severe disease.339
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Introduction: Autologous hematopoietic stem cell transplant (auto-
HCT) recipients have a high incidence of herpes zoster (HZ) follow-
ing transplant. The primary objective of this study was to estimate
the incremental medical resource utilization (RU) and costs associ-
ated with HZ in the auto-HCT population from HZ diagnosis
through 3 months after diagnosis with HZ.
Methods:Claims data (1999-2007) was assessed to determine the in-
cremental medical RU and cost due to HZ from Thomson Reuters
MarketScan Research Databases (Commercial and Medicare).
Cases were selected if they had an ICD-9-CM diagnostic code for
HZ following an ICD-9-CM procedure code for auto-HCT and
matched 1:1 via propensity scores to auto-HCT controls without
HZ. Differences in selected treatment and clinical characteristics
were assessed using t-tests for continuous variables and chi-square
tests for categorical variables. The analysis of resource use and costs
was limited to claims that could potentially be related to the treat-
ment of HZ. A two-part model (logistic regression / negative bino-
mial generalized linear model) was selected for multivariate
analysis of incremental medical RU and costs.
Results: One-hundred-twenty-four HZ cases were included in the
analysis (92% of these occurred within 2 years of the auto-HCTpro-
cedure). Over the 3 month analysis period, there were 20 hospitali-
zations with HZ as the principle diagnosis (0 for controls), 17
cases of ophthalmic HZ (0 for controls) and 21 cases with neurolog-
ical impairment due toHZ (0 for controls). There were no claims for
disseminated HZ or for the administration of IV acyclovir within 7
days of HZ diagnosis. Auto-HCT recipients with HZ had signifi-
cantly more medical service utilization in all categories (inpatient
admissions, average length of stay, emergency room visits, number
of outpatient visits, number of other outpatient services, and out
patient prescriptions) compared to controls (p\ 0.01). HCT pa-
tients with HZ had significant incremental medical costs due to
HZ (See Table 1).Table 1. Potentially HZ Related Medical Costs for auto-HCT
Recipients
N O bserved AdjustedAuto-HCTwith HZ 124 $8,229 $8,222
Auto-HCTwithout HZ 124 $1,526 $1,371Incremental Cost (95% CI) $6,703 $6,852 ($2,554 - $11,553)Conclusions: Herpes zoster has a significant impact on the health,
medical service use and medical costs for auto-HCT recipients. Fu-
ture advances for the treatment or prevention of HZ in auto-HCT
recipients should be given strong consideration to help alleviate
this medical burden.340
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Oral mucositis (OM) is a complication frequently associated with
hematopoietic stem cell transplantation (HSCT) following high-
dose chemotherapy with or without total body irradiation (TBI).
Severe OM increases the requirement for both IV opioids and total
parenteral nutritions (TPN), risk of infection, and subsequently pro-
longs the length of hospital stay (LOS). Palifermin, a keratinocyte
growth factor, is the only agent approved for the prevention of severe
OM in patients undergoing HSCT for hematologic malignancies.
The FDA-approved dosing of palifermin is 60 mcg/kg/day for 3
days pre-HSCT, followed by 60 mcg/kg/day for 3 days post-
HSCT. In limited data, collapsed-dose palifermin regimens offered
similar efficacy and safety profiles while providing more convenient
dosing schedules compared to the standard-dose regimen. Of the
two published collapsed-dose regimens, The Mount Sinai Medical
Center has adapted the following dosing schedule: 180 mcg/kg as
a single-dose pre-HSCT, followed by 60 mcg/kg/day for 3 consecu-
tive days post-HSCT. To compare the safety and efficacy between
the collapsed-dose and standard-dose palifermin, a 2-year retrospec-
tive study (June 2007 toMay 2009) was performed at our institution.
The primary objective was to assess the overall safety and efficacy of
collapsed-dose palifermin. The secondary objectives included asses-
ssment of the safety and efficacy of collapsed-dose palifemin with re-
duced intensity chemotherapy (RIC). Of the 81 patients treated with
palifermin, 43 received standard-dose, while 38 received collapsed-
dose. In the RIC group (n 5 35), 19 received standard-dose and 16
received collapsed-dose. Overall, there were no significant differ-
ences in the incidence of severe OM, requirements for TPN and
IV opioid usage, and the LOS between the two dosing groups; safety
profiles between the two dosing schedules have also been shown to
be comparable. Furthermore, a subgroup analysis in the RIC group
showed no significant differences in the incidence of severe OM, IV
opioid requirement, and LOS between the two dosing arms, with the
exception of the TPN requirement for which collapsed-dose arm
was associated with a higher rate of requirement than the stan-
dard-dose arm (63% vs. 26%, p5 0.04); the safety profile of palifer-
min between the two dosing groups have also been shown to be
similar. Our data supports the use of collapsed-dose palifermin as
a reasonable alternative to standard-dose palifermin regimen.341
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Background: Infections are a leading complication following cord
blood transplantation (CBT), but data on the rate of invasive fungal
infections (IFI) in this population are limited.
